Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts
- 1 June 1998
- journal article
- research article
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 28 (2-3) , 75-101
- https://doi.org/10.1007/bf02737806
Abstract
In order to study potential changes in phosphodiesterase (PDE) activity associated with malignant transformation, normal primary keratinocytes and cells corresponding to different stages of epidermal tumor development in mouse skin were analyzed with respect to their 3′,5′-cyclic adenosine monophosphate (cAMP) hydrolyzing activity. Expression of cAMP-specific PDE-4, intracellular cAMP content, and the sensitivity to the growth inhibitory effect of the PDE-4-specific inhibitor 7-benzylamino-6-chloro-2 piperazino-4-pyrrolidino-pteridine (DC-TA-46) were studied in the two papilloma cell lines, MSCP6 and 308, and in the highly malignant carcinoma cell line CarB. No significant difference in soluble PDE activity and in intracellular cAMP was found in the two papilloma cell lines when compared to primary keratinocytes. In contrast, the spindle-cell carcinoma cell line CarB exhibited significantly higher PDE activity, concomitant with the lowest cAMP level. In all cell lines and also in the primary keratinocytes, rolipram-sensitive PDE-4 activity accounted for the major cAMP-hydrolyzing activity. In primary keratinocytes and in MSCP6 cells, the PDE-4 inhibitor DC-TA-46 induced at best marginal growth inhibition, whereas cell growth of 308 cells was markedly affected at concentrations >2 μM. The carcinoma cell line CarB showed the highest sensitivity to DC-TA-46 (IC50=0.8±0.3 μM). Treatment of CarB cells with DC-TA-46 strongly inhibits intracellular PDE activity, resulting in a marked and long-lasting rise of cAMP. After 24 h of treatment, arrest in the G0/G1 phase of the cell cycle is induced. Treatment with concentrations >2 μM of this highly effective PDE inhibitor results in induction of apoptotic cell death, as detected by fluorescence microscopy, flow cytometry, and ELISA-based determination of fragmented DNA in intact cells.Keywords
This publication has 23 references indexed in Scilit:
- Novel and Potent Adenosine 3',5'-Cyclic Phosphate Phosphodiesterase III Inhibitors: Thiazolo[4,5-b][1,6]naphthyridin-2-onesJournal of Medicinal Chemistry, 1995
- Microinjected Catalytic Subunit of cAMP-Dependent Protein Kinase Induces Apoptosis in Myeloid Leukemia (IPC-81) CellsExperimental Cell Research, 1993
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Effect of Mopidamol on Survival in Carcinoma of the Lung and Colon: Final Report of Veterans Administration Cooperative Study No. 188JNCI Journal of the National Cancer Institute, 1988
- Isolation, characterization and in vitro cultivation of subfractions of neonatal mouse keratinocytes: effects of phorbol estersCarcinogenesis: Integrative Cancer Research, 1986
- Properties of carcinogen altered mouse epidermal cells resistant to calcium-induced terminal differentiationCarcinogenesis: Integrative Cancer Research, 1982
- Decreased basal cyclic adenosine 3′,5′-monophosphate levels in Morris hepatoma 5123 t.c.(h)Biochemical and Biophysical Research Communications, 1974
- Cyclic AMP dependent regulation of mitosis in human lymphoid cellsExperimental Cell Research, 1974
- Assay of phosphodiesterase with radioactively labeled cyclic 3?,5?-AMP as substrateNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1971